The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis

Veale, D. J. et al. (2019) The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology, 58(2), pp. 197-205. (doi: 10.1093/rheumatology/key070) (PMID:29618084) (PMCID:PMC6343466)

160353.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.



The pathogenesis of SpA is multifactorial and involves a range of immune cell types and cytokines, many of which utilize Janus kinase (JAK) pathways for signaling. In this review, we summarize the animal and pre-clinical data that have demonstrated the effects of JAK blockade on the underlying molecular mechanisms of SpA and provide a rationale for JAK inhibition for the treatment of SpA. We also review the available clinical trial data evaluating JAK inhibitors tofacitinib, baricitinib, peficitinib, filgotinib and upadacitinib in PsA, AS and related inflammatory diseases, which have demonstrated the efficacy of these agents across a range of SpA-associated disease manifestations. The available clinical trial data, supported by pre-clinical animal model studies demonstrate that JAK inhibition is a promising therapeutic strategy for the treatment of SpA and may offer the potential for improvements in multiple articular and extra-articular disease manifestations of PsA and AS.

Item Type:Articles
Additional Information:This work was funded by Pfizer Inc.
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain
Authors: Veale, D. J., McGonagle, D., McInnes, I. B., Krueger, J. G., Ritchlin, C. T., Elewaut, D., Kanik, K. S., Hendrikx, T., Berstein, G., Hodge, J., and Telliez, J.-B.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Rheumatology
Publisher:Oxford University Press
ISSN (Online):1462-0332
Published Online:03 April 2018
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in Rheumatology 58(2): 197-205
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record